Boosting levels of a protein called TFE3 helped reduce nerve cell degeneration and improve motor function in a mouse model of Parkinson’s disease, a study found. Increased levels of this protein helped clear toxic alpha-synuclein clumps, a hallmark of Parkinson’s, as well as restore the function of mitochondria, the…
Two imaging markers can help pinpoint sites of brain inflammation in people with Parkinson’s disease, according to a study. The findings shed light on the role of brain inflammation in disease progression and can help pave the way for more precise diagnostics and targeted therapies. “We are excited about…
Wearable sensors that monitor motor symptoms like tremor can accurately assess eligibility of Parkinson’s disease patients for apomorphine pump therapy, aligning closely with traditional clinical evaluations, according to a study. The findings suggest that wearable sensors have “the potential to revolutionize the way patients are assessed and treated, ultimately…
Cyrano Therapeutics is supporting an investigator-initiated clinical study that will evaluate CYR-064, its leading nasal candidate therapy, to restore smell loss in Parkinson’s disease. The study, led by neurologist David Silvers, MD, in Palm Beach Gardens in Florida, seeks to enroll 15 to 20 adults, ages 18-80, with…
Creative arts therapy, or an expressive therapeutic approach that engages people in various creative activities, can reduce anxiety in individuals with Parkinson’s disease and improve their well-being — while potentially lessening their need for healthcare services — according to the results of a small pilot study conducted in Europe.
Gain Therapeutics has set up a clinical advisory board made up of leading Parkinson’s experts in genetics, biomarkers, and trial design to guide the advancement of GT-02287, its investigational therapy for Parkinson’s disease. The advisory board will collaborate with Gain’s leadership to guide GT-02287 through its potential Phase…
A new screening method may shed light on the interactions between genetic variants that increase the risk of Parkinson’s disease, providing potential avenues for improving risk prediction and personalized care, a study found. The tool, Variant-variant Interaction through Variable Thresholds (VARI3), is designed to detect and interpret how genetic…
The motor cortex, a brain region responsible for movement control, becomes disconnected in levodopa-induced dyskinesia (LID), the uncontrolled movements that occur as a side effect of the drug levodopa in Parkinson’s disease, a study found. Ketamine, an anesthetic used to alleviate LID, was found to restore the motor cortex’s…
Serina Therapeutics has secured $10 million in new funding to support the development of its lead product, SER-252 (POZ-apomorphine), for treating advanced Parkinson’s disease. The goal, according to a company press release, is to advance the candidate therapy toward a Phase 1 clinical trial in patients by…
A fellowship worth more than $1.2 million will fund research focused on improving the mobility of individuals living with Parkinson’s disease. The Advanced Fellowship from the National Institute for Health and Care Research was awarded to Rosie Morris, PhD, director of the Physiotherapy Innovation Laboratory at Northumbria University, in…
Get regular updates to your inbox.
